Primary CNS lymphoma is rising in incidence in both the AIDS and non-AIDS populations. It is a non-Hodgkin's lymphoma that usually presents as a brain tumor, but the leptomeninges, eyes, and spinal cord also are
Primary CNS lymphoma is rising in incidence in both the AIDS and non-AIDS populations. It is a non-Hodgkin's lymphoma that usually presents as a brain tumor, but the leptomeninges, eyes, and spinal cord also are frequently affected. Systemic lymphoma is not present, and comprehensive systemic staging is unnecessary, but appropriate neurologic staging is imperative. Standard therapy has been whole brain radiotherapy, giving a median survival of 12 to 18 months in non-AIDS patients, but only 2 to 5 months in AIDS patients. In non-AIDS patients, the addition of chemotherapy to radiotherapy has improved the prognosis, with median survivals of 30 to 45 months. Current protocols focus on the development of combination chemotherapy programs and reducing the dose of cranial radiotherapy to minimize late neurologic sequelae. The addition of chemotherapy to brain irradiation prolongs survival in some patients with AIDS-related disease, but median survival is not significantly improved.
Primary central nervous system (CNS) lymphoma is a non-Hodgkin's lymphoma that arises within and is restricted to the nervous system. It usually presents as a brain tumor, but may also involve the leptomeninges, eyes, spinal cord, or any combination of these sites . Formerly, the disease was rare, representing less than 1% of all intracranial tumors, but since 1974 there has been at least a threefold rise in incidence in apparently immunocompetent patients. It has also been recognized for decades that primary CNS lymphoma occurs with increased frequency in patients with congenital (eg, ataxia-telangiectasia) or acquired (eg, renal transplant recipients) immunodeficiencies. It is now most common in patients with the acquired immunodeficiency syndrome (AIDS), as many as 6% of whom develop primary CNS lymphoma during their illness. It is so characteristic of the immunosuppression associated with AIDS that it is classified as an AIDS-defining illness in HIV-infected individuals.
Historically, treatment of primary CNS lymphoma was surgery followed by cranial irradiation; the median survival was 12 to 18 months, and the 5-year survival rate, 3% to 4% in immunocompetent patients; immunosuppressed individuals fared worse. Survival figures with this treatment approach were consistent in numerous retrospective series evaluating small numbers of patients (20 to 30) collected over several decades. These studies also demonstrated the aggressive biologic behavior of primary CNS lymphoma, with untreated patients surviving only a few months. Furthermore, the collected series suggested that surgical resection had no significant therapeutic role in the treatment of this disease, because survival was not worsened if only biopsy for tissue diagnosis was performed. Because the disease was so infrequent, pursuit of more effective therapy seemed neither practical nor necessary.
In the early 1980s, physicians began to see a rising number of immunocompetent patients with primary CNS lymphoma, an increase later confirmed by epidemiologic data. During this time, the full force of the AIDS epidemic led to increased cases of AIDS-related primary CNS lymphoma, and recent studies demonstrate that the incidence continues to rise, as HIV-infected individuals survive longer [2,3]. These factors clearly highlighted the inadequacy of then-current therapy, and clinical trials were begun in an effort to improve treatment.
To design an appropriate therapeutic approach, a number of issues concerning the biologic behavior of primary CNS lymphoma needed to be defined and incorporated into the treatment plan. Using the clinical staging criteria applied to systemic non-Hodgkin's lymphoma, primary CNS lymphoma is a stage IE lymphoma; that is, it involves a single extranodal site, the brain. Most patients with systemic stage Ie non-Hodgkin's lymphoma can be treated effectively with involved field irradiation. Focal radiotherapy achieves a complete response rate of almost 100% and can yield 10-year survival or cure rates of 70% in patients with stage I disease . Using involved field radiotherapy (whole brain radiotherapy) for the treatment of primary CNS lymphoma does not produce comparable control of disease. Two possible reasons are that (1) disease exists outside the radiotherapy field and that (2) pathologically, primary CNS lymphoma has more aggressive biology than identical systemic lymphomas.
The issue of dissemination of disease is more easily addressed than the question of a fundamental biologic difference between primary CNS lymphoma and systemic lymphomas, but systemic and nervous system dissemination must be considered independently.
It has been hypothesized that an occult systemic lymphoma is the origin of primary CMS lymphoma, because the nervous system has no lymph nodes or lymphatics, and thus the source of malignant lymphocytes in the CNS must be from outside. If an occult systemic lymphoma accounts for disease in the nervous system, then primary CNS lymph- oma would simply be a stage IV lymphoma with an unusual and rare pattern of metastasis to CNS only. However, the evidence argues strongly against this hypothesis.
First, when systemic lymphoma spreads to the nervous system, it spreads to meninges and affects the brain in only 1% of patients . In those few patients with brain metastases, the lesions appear late in the course of their illness and are associated with recurrent or uncontrolled systemic disease, often specifically with bone marrow infiltration or retroperitoneal adenopathy.
Second, patients with primary CNS lymphoma have no evidence of systemic lymphoma, either at diagnosis or at autopsy. At Memorial Sloan-Kettering Cancer Center, more than 100 non-AIDS patients with primary CNS lymphoma had a complete systemic evaluation at diagnosis, including body computed tomography (CT) scans, bone marrow aspiration, and biopsy, and not one had evidence of systemic lymphoma. There are two case reports of patients who presented with apparent primary CNS lymphoma and had systemic lymphoma on evaluation, but one patient had two histologically different lymphomas, and the disease in the second patient likely represented systemic metastases from untreated primary CNS lymphoma [6,7].
Autopsy studies have found systemic lymphoma in only 7% to 8% of primary CNS lymphoma patients, and most of these patients have a single site of microscopic disease believed to be a metastasis from their uncontrolled CNS tumor. Rare patients with primary CNS lymphoma develop clinically obvious systemic lymphoma, which may even develop in the context of undetectable cerebral tumor. In some of these patients, the systemic lymphoma may be a second primary, as primary CNS lymphoma is seen occasionally in patients with a variety of prior systemic neoplasms ; however, the development of systemic lymphoma is very unusual and does not represent the typical clinical behavior of primary CNS lymphoma.
These data demonstrate that systemic lymphoma is not a factor in the natural history of primary CNS lymphoma, and that treatment need not include therapy designed to eradicate occult systemic disease.
Although systemic dissemination is not a factor when considering treatment of primary CNS lymphoma, dissemination within the nervous system must be considered (Table 1). Primary CNS lymphoma is confined to a single extranodal site, the central nervous system, but is almost always disseminated within it. This dissemination can take many forms and involve different compartments of the CNS. The brain is the most important site of disease and is involved in more than 95% of patients . By magnetic resonance (MR) scan, parenchymal brain lymphoma is multifocal in about half of patients at diagnosis. However, autopsy and some radiographic studies have demonstrated that the contrast-enhancing lesions seen on scan can significantly underestimate the extent of tumor present within the parenchyma . At autopsy, all patients have microscopic infiltration involving regions of brain and occasionally spinal cord that were radiographically normal. Consequently, the tumor burden is always greater than initially appreciated, and if enhancement on CT or MR scan measures blood-brain barrier integrity, all patients have some disease behind a relatively intact blood-brain barrier.
The Brain-The brain is the most important area of involvement by primary CNS lymphoma, but dissemination within other CNS compartments, such as the leptomeninges, eyes, and spinal cord, may also be important, and appropriate neurologic staging, including lumbar puncture and ophthalmologic examination, is imperative (Table 2). Primary CNS lymphoma tends to form mass lesions in periventricular locations. It is a highly infiltrative neoplasm and will usually traverse the ependyma to involve the ventricular surface. Lesions more peripherally located grow into the overlying leptomeninges. Leptomeningeal infiltration is so characteristic of primary CNS lymphoma that Shibata10 has postulated that malignant lymphocytes from the subarachnoid space are the source of primary CNS lymphoma and grow into the brain to form parenchymal mass lesions.
The Leptomeninges-In many patients, leptomeningeal involvement remains localized to areas adjacent to the parenchymal lesions, accounting for the absence of clinical symptoms or signs specifically suggestive of leptomeningeal tumor, such as cranial neuropathies or radiculopathies (!-Figure 1). In spite of the relatively localized leptomeningeal involvement seen pathologically, malignant cells are identified in the cerebrospinal fluid (CSF) of one third of patients at diagnosis; in an additional third, lymphocytes with a suspicious cytology are present . Thus, there is a high incidence of at least microscopic CSF dissemination of primary CNS lymphoma at diagnosis.
In occasional patients, widespread leptomeningeal lymphoma with clinical evidence of subarachnoid tumor may be the presenting problem, but these patients are a distinct minority. Nevertheless, most patients have tumor within the leptomeninges, at the gross or microscopic level, and thus specific therapy must be directed against the CSF.
The Eyes-In addition to the leptomeninges, the eye is another important site of primary CNS lymphoma [12-14]. Embryologically and functionally, the eye is an extension of the nervous system. Occasionally, ocular involvement (as opposed to orbital lymphoma, which always represents systemic disease) occurs by direct extension of brain disease through the optic nerve or meninges, but more commonly it arises as an independent site of this multifocal process . Patients may present with blurred vision or floaters, but clinically this may be hard to distinguish from more common benign ocular conditions, particularly in an older population. In the AIDS population, these symptoms may be confused with ocular infections, particularly cytomegalovirus (CMV) retinitis. In addition, about half of patients with ocular lymphoma have no visual symptoms.
About 12% to 18% of patients in whom primary CNS lymphoma began in the brain have ocular involvement at diagnosis.11 Conversely, lymphoma can begin in the globe, and 50% to 80% of patients with ocular lymphoma develop cerebral involvement during the course of their disease. Frequently, the latency from onset of ocular lymphoma to the appearance of CNS disease is many years. Ocular lymphoma is detected by slit-lamp ophthalmologic examination. Vitrectomy may demonstrate malignant lymphocytes, but such a biopsy may yield a false negative if the patient has been taking corticosteroids .
While the relationship between ocular and cerebral lymphoma has been known for years, ophthalmologic examination has only recently become part of the staging evaluation of patients with primary CNS lymphoma, and, therefore, clinically silent ocular infiltration was not detected previously. This has important therapeutic implications, since ocular involvement necessitates specific therapy, which is not administered in the course of standard whole brain radiotherapy. Neglect of ocular lymphoma not only results in progressive ocular disease with visual loss but also can lead to CNS relapse and an apparent failure of standard treatment.
The Spinal Cord-Parenchymal spinal cord involvement is rare and usually clinically evident; however, we have encountered a few patients with spinal cord infiltration missed at diagnosis and not covered by the initial therapy. Complete imaging of the spinal cord is not necessary in every patient with primary CNS lymphoma, but patients with neck or back pain, and symptoms or signs suggestive of myelopathy should have an enhanced MR scan of the entire spine. Very rarely, primary CNS lymphoma originates within the spinal cord, but localization of the disease is usually straightforward, since patients present with progressive paraplegia .
In virtually all patients, primary CNS lymphoma is disseminated throughout the nervous system at diagnosis. While almost all patients present with brain tumor(s), many will have involvement of the eyes, leptomeninges, spinal cord, or some combination of these sites. These regions must be incorporated into a treatment regimen or they will serve as a potential reservoir of untreated disease that will lead to subsequent relapse. Nevertheless, failure to cover sites of dissemination accounts for treatment failure in only about 10% of patients.
In about 90%, primary CNS lymphoma relapses occur in the brain, often at sites remote from the original tumor location. Some brain recurrences may be attributed to progression from ocular or meningeal sites, but uncontrolled brain lymphoma is the most likely source for the majority of relapses. Relapse within the irradiated field is common after focal radiotherapy for primary CNS lymphoma, unlike stage IE systemic lymphoma, indicating that primary CNS lymphoma is a more biologically aggressive disease than comparably staged systemic non-Hodgkin's lymphoma . No molecular features responsible for this biologic aggression have been identified.
The problem of nervous system dissemination is also applicable to AIDS-related primary CNS lymphoma. Most non-Hodgkin's lymphomas in AIDS patients arise in extranodal sites; the brain is the single most common location [17,18]. Central nervous system metastases, usually leptomeningeal, are especially common in AIDS patients with systemic non-Hodgkin's lymphoma. Although no AIDS patient has been reported with systemic lymphoma presenting as an intracranial mass lesion, this remains at least a theoretical possibility. At present, it is prudent to do a systemic staging evaluation with body CT scans and bone marrow biopsy on all AIDS patients with primary CNS lymphoma (Table 2).
Dissemination of primary CNS lymphoma throughout the nervous system is particularly striking in AIDS patients. Multifocal primary CNS lymphoma occurs in virtually 100% of AIDS patients at autopsy, and leptomeningeal spread is often pronounced [19,20]. Ocular disease can occur in AIDS-related primary CNS lymphoma, but its incidence is unknown, since few patients have been studied prospectively. Cerebrospinal fluid involvement is common, and CSF cytology establishes the diagnosis in 30% of our patients .
A lumbar puncture should be performed in every patient with a mass lesion, to identify this significant minority of patients whose primary CNS lymphoma can be diagnosed immediately and appropriate therapy instituted. Lumbar puncture is safe in almost all patients with primary CNS lymphoma, AIDS and non-AIDS; we avoid lumbar puncture for fear of cerebral herniation only in patients with large posterior fossa lesions. This is particularly important in AIDS patients, because most who have an intracranial mass lesion identified on CT/MR scan are placed on empiric anti-toxoplasmosis therapy for 2 to 3 weeks to treat the most common cause of cerebral lesions in this population. However, primary CNS lymphoma is the second most common cause, and patients with primary CNS lymphoma usually deteriorate neurologically while on antibiotics. This deterioration may not be recovered once the correct diagnosis is made on brain biopsy, and poor neurologic condition frequently contributes to the patient's early demise. Two circumstances warrant consideration of an early brain biopsy:
1. The patient with negative toxoplasmosis titers.
2. The patient who has clear clinical deterioration within the first week of anti-toxoplasmosis treatment.
Primary CNS lymphoma in the AIDS population presents other unique issues. In the non-AIDS patient, mortality is determined by the successful treatment of the tumor; however, in AIDS patients, mortality is affected not only by the tumor but also by systemic and neurologic infections [21,22]. Depending on the series, 25% to 100% of autopsied AIDS patients with primary CNS lymphoma have coexistent CNS infections, including HIV encephalitis, toxoplasmosis, cryptococcal meningitis, CMV encephalitis, and others [19,20]. Often, multiple infections are present. Many of these infections are not easily diagnosed prior to autopsy or do not have effective therapies. They confound the clinical assessment of primary CNS lymphoma treatment and often lead to the patient's death even when the primary CNS lymphoma has been eradicated. Likewise, systemic opportunistic infections frequently result in death during or after successful treatment. These factors explain the much poorer outcome of primary CNS lymphoma in AIDS patients compared with identical treatment in the non-AIDS population.
The development of new therapies for primary CNS lymphoma in immunocompetent patients has, to some extent, paralleled recent therapeutic developments for bulky stage I and II systemic non-Hodgkin's lymphomas. Patients with geographically limited but large-volume systemic lymphoma are at risk for relapse after treatment with focal irradiation because of microscopic disease that had spread beyond the radiotherapy port but was not detected by standard staging strategies. Medical oncologists began treating these patients more aggressively, using combination chemotherapy regimens successful in the treatment of more advanced lymphomas. The addition of chemotherapy to focal radiotherapy has significantly prolonged disease-free survival and increased the cure rate for patients with intermediate- or high-grade lymphomas [23,24].
In primary CNS lymphoma, systemic chemotherapy was initially used in the treatment of individual patients who relapsed after cranial irradiation. Patients received single-agent therapy, using drugs that penetrated into the CNS when delivered in high doses, such as methotrexate and cytarabine [25-27]. Complete or substantial partial remissions of primary CNS lymphoma or metastatic brain lymphoma were seen in the few patients reported, but remission duration was only a few months. Nevertheless, this preliminary work established the chemosensitivity of primary CNS lymphoma and pointed to some potentially useful drugs.
In the early 1980s, there were reports of combining chemotherapy with radiation as initial treatment. Most of the regimens used methotrexate or a nitrosourea-based regimen because of the lipophilic nature of these drugs and their ability to penetrate into the nervous system [28,29]. Individual patients often received different regimens, and patients were not treated in a uniform manner, but there was suggestive evidence that combined modality therapy was superior to cranial irradiation alone.
Memorial Sloan-Kettering Study-Subsequently, there have been several reports documenting improved survival when chemotherapy is added to radiotherapy (Table 3). At Memorial Sloan-Kettering Cancer Center, we treated 31 patients with preradiation systemic and intra-Ommaya methotrexate, followed by radiotherapy and high-dose cytarabine . Our latest follow-up, as of April, 1994, confirmed a disease-free median survival of 41 months, and our longest survivor is now 9 years without recurrence. We have recently found that age is an important prognostic factor; patients younger than 50 have significantly better response and longer survival than those older than 50. Furthermore, late neurologic toxicity in the form of dementia and ataxia does not occur in younger patients, but has a 27% incidence among older patients who achieve a complete response.
Other Studies-Using a combination of procarbazine, CCNU, and vincristine (PCV) with radiotherapy, Chamberlain and Levin31 achieved a median survival of 30 months. Gabbai et al  have used single-agent high-dose methotrexate with cranial irradiation with good results; 3 of 13 patients were alive at 29 months or longer. Pollack et al  reported on 9 patients, Socie et al  on 13 patients, and Watne et al  on 9 patients who received a variety of chemotherapeutic agents; all noted an increase in survival over patients treated with radiotherapy alone. All of these studies strongly support the addition of chemotherapy to cranial irradiation as initial treatment of primary CNS lymphoma, but all are phase II trials. No randomized controlled study has been performed, nor is it likely to be done because of the relative rarity of this tumor and the seeming consistency of the results.
The Rationale Behind Chemotherapy Followed By Radiation-All of these studies have utilized chemotherapy prior to radiation for several reasons:
First, it permits an assessment of response to treatment. Almost all patients have a complete, albeit short-lived, response after radiotherapy alone, and therefore no measurable disease is present during postradiation chemotherapy administration. This is particularly important in primary CNS lymphoma because we are still learning about the efficacy of individual agents, as it has become apparent that one cannot simply adopt regimens that are effective for the treatment of comparable systemic non-Hodgkin's lymphomas (see below).
Second, the administration of drugs prior to radiation may reduce the risk of late neurotoxicity, particularly with methotrexate. Data from children with acute lymphocytic leukemia treated with CNS prophylaxis indicate that late neurologic sequelae are less common and less severe when methotrexate precedes cranial irradiation, compared with simultaneous or postradiotherapy administration . Experimental evidence suggests that methotrexate prior to cranial radiotherapy may even be protective against late neurologic toxicity in laboratory animals .
Although this issue has been studied only for methotrexate, the toxicity concerns may apply to other agents as well. Opening of the blood-brain barrier by cranial irradiation can persist for weeks to months after completion of radiotherapy . This persistent breakdown of the blood-brain barrier is the postulated mechanism to explain the enhanced neurotoxic potential seen when methotrexate follows radiotherapy, since greater concentrations of drug can accumulate in normal brain tissue. Clearly, any water-soluble agent would have greater access to normal brain tissue if delivered after whole brain radiotherapy.
Non-conventional Delivery Systems-Most regimens have employed agents delivered in a conventional manner, but alternative approaches have also been used successfully. Neuwelt et al  have pioneered the technique of blood-brain barrier disruption with intra-arterial mannitol followed by intra-arterial methotrexate in combination with systemic cyclophosphamide (Cytoxan, Neosar), procarbazine, and dexamethasone. This regimen is designed to treat the entire CNS by delivering therapy to all three cerebral circulations in a rotating fashion over the course of 1 year. The intent of this program is to treat primary CNS lymphoma with chemotherapy alone, thus avoiding cranial irradiation and its attendant neurotoxicity.
Neuwelt et al have reported on 17 patients treated with this regimen at diagnosis. Sixteen patients were evaluable, and they had a median survival of 44.5 months. However, nine of these patients required radiotherapy, and the time to relapse was not reported. The regimen was reported to be nontoxic, although this may be a direct reflection of the considerable experience and skill these investigators have developed using this technique over the years and may not be applicable at less experienced centers.
CHOP and CHOD-Several investigators have used or adopted chemotherapeutic regimens successful in the treatment of systemic non-Hodgkin's lymphoma for primary CNS lymphoma. One would expect the disease to be sensitive to the same drugs and hopefully to achieve the same remission and cure rates; however, these regimens have proved uniformly ineffective. Stewart et al  first utilized cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with radiotherapy, but reported that after an initial response to chemotherapy, patients went on to develop florid leptomeningeal tumor, which progressed and led to death. At Memorial Sloan-Kettering, we treated five patients with CHOD (dexamethasone replacing prednisone) at recurrence. Only one patient achieved a complete response, and the other four had progressive disease (two) or developed refractory leptomeningeal lymphoma (two) . Lachance et al  used CHOP followed by neuraxis radiotherapy at diagnosis. All patients had an initial response to CHOP, but developed multifocal recurrence in sites remote from the original areas of disease before chemotherapy could be completed.
The RTOG and Other Studies-CHOD received its most extensive assessment in a recently completed study conducted by the Radiation Therapy Oncology Group (RTOG) . The study called for three cycles of chemotherapy followed by definitive radiation. Preliminary results show a median survival of only 12.8 months for the 51 patients treated. Furthermore, it appears that when effective, CHOP may be associated with a high incidence of delayed neurologic toxicity. Liang et al  reported enhanced efficacy with CHOP and intrathecal methotrexate and cranial irradiation, seeing a median survival of 30 months in nine patients so treated. However, eight of their nine patients received all or at least half of their chemotherapy after radiation, and they had a very high incidence of leukoencephalopathy (seven of nine patients) with cognitive decline in five of the seven. Brada et al  combined the MACOP-B regimen with cranial radiotherapy, but had a median survival of only 14 months, no better than radiation alone.
Those regimens that failed to prolong survival over that seen with radiotherapy alone are based upon cyclo- phosphamide and doxorubicin, unquestionably the best agents for the treatment of non-Hodgkin's lymphomas. However, neither of these drugs penetrates an intact blood-brain barrier. Reasonable concentrations are likely achieved in areas of bulky disease clearly seen on contrast-enhanced cranial scans, which account for the initial response to these regimens with reduction of tumor masses. However, the rapid appearance of progressive tumor in areas that had a relatively intact blood-brain barrier (the leptomeninges and regions remote from the original disease) further supports the concept of disseminated nervous system disease at diagnosis and highlights the importance of using agents that can reach these areas.
This is supported by some experimental work done by Ott et al on a patient treated with the MACOP-B regimen . Blood-brain barrier integrity was studied by positron emission tomography (PET) prior to, during, and after chemotherapy. As expected, the blood-brain barrier was markedly abnormal in regions of disease seen on cranial MR/CT scan, but the barrier was reconstituted and normal permeability was restored halfway through the chemotherapeutic regimen. Consequently, no effective agents could reach tumor throughout half of the therapeutic program, even in areas where the blood-brain barrier was initially impaired.
These data strongly argue for the use of drugs that penetrate an intact blood-brain barrier to reach all areas of tumor. Furthermore, the history of treatment for systemic non-Hodgkin's lymphomas documents the superiority of combination chemotherapy over single agents, and this may be particularly important in the treatment of primary CNS lymphoma, since some of the best antilymphoma agents are not useful in this setting. Consequently, new protocols are being used that attempt to combine these two requirements (using multiple drugs that penetrate the blood-brain barrier).
At Memorial Sloan-Kettering Cancer Center, we are currently studying preradiation high-dose methotrexate (2.5 g/m2), procarbazine, and vincristine delivered over a 10-week period followed by whole brain radiotherapy and high-dose cytarabine (3 g/m²) for two cycles. This regimen will be implemented in an intergroup trial through RTOG and the Southwest Oncology Group (SWOG) later this year, and therefore will be available to many physicians.
Most of the chemotherapy studies have focused on the use of preradiation chemotherapy. What about the patient who is first referred after cranial irradiation has already been administered? Is there a role for adjuvant chemotherapy? This question has not been adequately studied, and we do not know if adjuvant chemotherapy is equivalent to preradiation drug. However, some preliminary evidence suggests that it is superior to radiotherapy alone. Chamberlain and Levin gave their PCV regimen after cranial radiotherapy . Unlike methotrexate, these drugs do not potentiate the delayed toxic effects of radiotherapy, and no enhanced neurotoxicity was reported. We have chosen to give four to six cycles of PCV after completion of cranial radiotherapy to those patients who received no prior chemotherapy. These patients usually have had a complete response to radiotherapy, and there is no measurable disease to follow, making an assessment of the regimen's efficacy impossible during its administration. We have avoided methotrexate and even high-dose cytarabine as adjuvant drugs in this setting because of the toxicity issues, despite their known activity against primary CNS lymphoma.
The addition of chemotherapy is the most important recent advance in the treatment of primary CNS lymphoma; however, some radiotherapeutic issues have also been clarified. A dose-response study has never been done for this tumor, but retrospective data suggest that 4,000 to 5,000 cGy improves survival over lower doses . The RTOG completed a prospective study of non-AIDS patients with primary CNS lymphoma treated with 4,000 cGy whole brain radiotherapy plus a 2,000 cGy boost to the involved area, to assess whether dose intensification improved outcome . The median survival for the group as a whole was only 12.2 months, and most recurrences were in the boosted field. In this study, young age (less than 60 years) and better performance status were identified as important prognostic factors.
In our study of patients receiving preradiation methotrexate and high-dose cytarabine after radiation, patients received 4,000 cGy whole brain radiotherapy plus 1,440 cGy boost to the tumor bed . In patients who recurred, relapse occurred within the boosted region as frequently as outside the boosted area, suggesting that the added radiotherapy did little to improve local control. This is in keeping with data obtained from systemic non-Hodgkin's disease, for which a dose of 4,200 cGy is optimal to treat stage I and II disease . Furthermore, the risk of late neurologic sequelae increases with increasing radiation dose. Consequently, we have eliminated the boost and now use 4,500 cGy whole brain irradiation in our current therapeutic protocol. This should provide maximal efficacy and reduced toxicity.
Ocular lymphoma deserves special consideration. Ocular involvement is almost always a bilateral process, although it may be asymmetric. Radiotherapy is the most important therapeutic modality to treat ocular lymphoma, and both eyes should be irradiated to a total dose of approximately 3,600 cGy [12,48]. When ocular lymphoma is present at diagnosis of cerebral lymphoma, the ocular radiotherapy must be administered concurrently with the whole brain irradiation to eliminate the problem of overlapping ports in the region of the optic nerve and posterior retina. If a patient who has had prior cranial irradiation develops an ocular recurrence, ocular radiotherapy can still be administered, but must be done with great care to avoid overlap and the subsequent complications of radiation-induced optic atrophy or retinal degeneration. Ocular irradiation is usually effective in reducing or eliminating cells in the vitreous or retina, and in improving vision. Remissions may be durable for many years, or local recurrence can develop within months.
Treatment of patients with isolated ocular lymphoma is controversial. Previously, these patients all received focal ocular radiotherapy alone. However, because of their high incidence of subsequent cerebral lymphoma, several investigators have advocated treating such patients with ocular and whole brain radiotherapy . To date, there are no data to suggest that this approach reduces the incidence of brain lymphoma. Because CNS radiotherapy is potentially toxic, and the latency between ocular lymphoma and eventual brain disease can be many years, we administer only ocular radiotherapy to patients with isolated ocular lymphoma. Further investigation may clarify this issue in the future.
Chemotherapy has limited efficacy in the treatment of ocular lymphoma because penetration of most chemotherapeutic agents into the vitreous is so poor. The best agent is high-dose cytarabine (3 g/m²), which can clear the vitreous of malignant cells, often for prolonged periods of time [12,49]. Cytarabine may be used for recurrent ocular disease, but the role of adjuvant chemotherapy is not clear in the treatment of ocular lymphoma at diagnosis. Other drugs have been reported to be of use in isolated instances, but there is much less experience with these agents.
In spite of the best treatment, many patients develop recurrent primary CNS lymphoma involving brain, eyes, leptomeninges, or some combination. Most patients will have already received cranial irradiation, but may be eligible to receive ocular or focal spinal radiotherapy for recurrent disease in these areas. However, chemotherapy is the mainstay of treatment for recurrent disease. The choice of drug is determined by the patient's previous chemotherapy exposure and the location of the recurrence (eg, high-dose cytarabine for relapsed ocular lymphoma). The best agents are those described above for the initial treatment of primary CNS lymphoma. Although the chemotherapeutic options are more limited for primary CNS lymphoma than for systemic lymphoma, durable second remissions of a few years may be obtained in some patients.
The treatment modalities for primary CNS lymphoma in immunocompetent patients are also used to treat AIDS-related primary CNS lymphoma, although in general they are less effective and more toxic in immunodeficient patients. Cranial irradiation alone gives a median survival of only 2 to 5 months in AIDS-related primary CNS lymphoma, compared with 12 to 18 months in the non-AIDS patient [22,50-52]. For most patients, radiotherapy achieves an excellent partial or complete response, but patients do not always experience a commensurate improvement in their neurologic condition, due to coexistent CNS infections. Although systemic and neurologic infections are a major cause of death in AIDS patients with primary CNS lymphoma, many die of uncontrolled cerebral lymphoma.
Chemotherapy has been added to radiotherapy in a small number of patients in an effort to improve response duration. Gill et al  reported two patients who survived 28+ and 16 months after systemic chemotherapy (type unknown) and radiotherapy, and Formenti et al  reported one patient who survived 16 months. Chamberlain  gave whole brain radiotherapy followed by three cycles of PCV to four patients with AIDS-related primary CNS lymphoma and saw survivals of 11 to 16 months, with a median of 13.5 months.
At Memorial Sloan-Kettering Cancer Center, we have treated 10 patients with chemotherapy, nine at diagnosis and one at relapse after radiotherapy alone . Two patients died of treatment-related complications. Seven of the other eight had a response to treatment (88%). The median survival for all 10 patients was only 3.5 months, and was 7 months for the eight patients who completed therapy. Although these median survivals are not different from treatment with whole brain irradiation alone, two patients survived for 1 year or longer, and one is still alive at 54 months after diagnosis. Toxicity was primarily due to myelosuppression and the development of intercurrent infections, but no toxic deaths occurred after colony stimulating factors became clinically available. Concurrent cytotoxic drugs such as zidovudine (Retrovir) or ganciclovir (Cytovene) should be discontinued during chemotherapy until there has been full recovery from any myelotoxicity.
These data suggest that some AIDS patients may benefit from a more vigorous therapeutic approach. The best candidates are those with CD4 counts greater than 200/mm³, a good performance status, and no active comorbid conditions . Other patients who are in poor clinical condition, have CD4 counts less than 50/mm³, and are not expected to survive more than 2 months are best treated with palliative radiotherapy. In some patients, a rapid fractionation schedule, such as 3,000 cGy in 10 fractions, may be most appropriate.
1. DeAngelis LM: Primary CNS lymphoma, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Principles and Practice of Oncology Updates. Philadelphia, JB Lippincott, 1992.
2. Pluda JM, Yarchoan R, Jaffe ES, et al: Development of non-Hodgkin lymphoma in a cohort of patients with severe HIV infection on long-term antiretroviral therapy. Ann Intern Med 113:276-282, 1990.
3. Levine AM: AIDS-related malignancies: The emerging epidemic. J Natl Cancer Inst 85:1382-1397, 1993.
4. Vokes EE, Ultmann JE, Golomb HM: Long-term survival of patients with localized diffuse histiocytic lymphoma. J Clin Oncol 3:1309, 1985.
5. Levitt LJ, Dawson DM, Rosenthal DS, et al: CNS involvement in the non-Hodgkin's lymphomas. Cancer 45:545-552,1980.
6. Weissman DE, Kueck BD, Merkow AB: A case of large cell CNS lymphoma associated with a systemic small cell lymphocytic lymphoma. J Neurooncol 9:171-175, 1990.
7. Herman MD, Gordon LI, Kaul K, et al: Systemic T-cell lymphoma presenting with isolated neurological dysfunction and intraparenchymal brain lesions. J Neurosurg 78:997-1001, 1993.
8. DeAngelis LM: Primary central nervous system lymphoma as a secondary malignancy. Cancer 67:1431-1435, 1991.
9. DeAngelis LM: Cerebral lymphoma presenting as a nonenhancing lesion on computed tomographic/magnetic resonance scan. Ann Neurol 33:308-311, 1993.
10. Shibata S: Sites of origin of primary intracerebral malignant lymphoma. Neurosurgery 25:14-19, 1989.
11. DeAngelis LM, Yahalom J, Heinemann MH: Primary CNS lymphoma: Combined treatment with chemotherapy and radiotherapy. Neurology 40:80-86, 1990.
12. Peterson K, Gordon KB, Heinemann MH, et al: The clinical spectrum of ocular lymphoma. Cancer 72:843-849, 1993.
13. Buettner H, Bolling JP: Intravitreal large-cell lymphoma. Mayo Clin Proc 68:1011, 1993.
14. Whitcup SM, deSmet MD, Rubin BI, et al: Intraocular lymphoma clinical and histopathologic diagnosis. Ophthalmology 100:1399, 1993.
15. Qualman SJ, Mendelsohn G, Mann RB: Intraocular lymphomas, natural history based on a clinicopathologic study of eight cases and review of the literature. Cancer 52:878-886, 1983.
16. Goffman TE, Glatstein E: CNS lymphoma: Back to the drawing board. Int J Radiat Oncol Biol Phys 23:247-248, 1992.
17. Kaplan LD, McGrath MS: AIDS-associated non-Hodgkin's lymphoma. AIDS Updates 4:1-11, 1991.
18. Levine AM: Non-Hodgkin's lymphomas and other malignancies in AIDS. Semin Oncol 14:34-39, 1987.
19. Morgello S, Petito CK, Mouradian JA: Central nervous system lymphoma in AIDS. Clin Neuropathol 9:205-215, 1990.
20. So YT, Beckstead JH, Davis RL: Primary central nervous system lymphoma in acquired immune deficiency syndrome: A clinical and pathological study. Ann Neurol 20:566-572, 1986.
21. Forsyth PA, Yahalom J, DeAngelis LM: Combined modality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology 44:1473-1479, 1994.
22. Baumgartner JE, Rachlin JR, Beckstead JH, et al: Primary central nervous system lymphomas: Natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg 73:206-211, 1990.
23. Yahalom J, Varsos G, Fuks Z, et al: Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemo after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin's lymphoma. Cancer 71:2342, 1993.
24. Tondini C, Zanini M, Lombardi F, et al: Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas. J Clin Oncol 11:720-725, 1993.
25. Abelson HT, Kufe DW, Skarin AT: Treatment of central nervous system tumors with methotrexate. Cancer Treat Rep 65:137-140, 1981.
26. Frick JC, Hansen RM, Anderson T, et al: Successful high-dose intravenous cytarabine treatment of parenchymal brain involvement from malignant lymphoma. Arch Intern Med 146:791-792, 1986.
27. Ervin T, Canellos GP: Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate. Cancer 45:1556-1557, 1980.
28. Loeffler JS, Ervin TJ, Matich P, et al: Primary lymphomas of the central nervous system: Patterns of failure and factors that influence survival. J Clin Oncol 3:490-494, 1985.
29. Kawakami Y, Tabuchi K, Ohnishi R: Primary central nervous system lymphoma. J Neurosurg 62:522-527, 1985.
30. DeAngelis LM, Yahalom J, Thaler HT, et al: Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10:635-643, 1992.
31. Chamberlain MC, Levin VA: Adjuvant chemotherapy for primary lymphoma of the CNS. Arch Neurol 47:1113-1116, 1990.
32. Gabbai AA, Hochberg FH, Linggood RM, et al: High-dose methotrexate for non-AIDS primary central nervous system lymphoma. J Neurosurg 70:190-194, 1989.
33. Pollack IF, Lunsford LD, Flickinger JC, et al: Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer 63:939-947, 1989.
34. Socie G, Piprot-Chauffat C, Schlienger M, et al: Primary lymphoma of the central nervous system. Cancer 65:322-326, 1990.
35. Watne K, Scott H, Hager B: Primary malignant lymphoma of the brain: A report of 24 cases from the Norwegian Radium Hospital. Acta Oncol 31:545-550, 1992.
36. Bleyer WA: Neurologic sequelae of methotrexate and ionizing radiation: A new classification. Cancer Treat Rep 65:89-98, 1981.
37. Geyer JR, Taylor EM, Milstein JM: Radiation, methotrexate, and white matter necrosis: Laboratory evidence for neural radioprotection with preirradiation methotrexate. Int J Radiat Oncol Biol Phys 15:373-375, 1988.
38. Delattre JY, Shapiro WR, Posner JB: Acute effects of low-dose cranial irradiation on regional capillary permeability in experimental brain tumors. J Neurol Sci 90:147-153, 1989.
39. Neuwelt EA, Goldman DL, Dahlborg S: Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function. J Clin Oncol 9:1580-1590, 1991.
40. Stewart DJ, Russell N, Dennery M, et al: Cyclophosphamide, Adriamycin, vincristine and dexamethasone in the treatment of bulky CNS lymphomas. J Neurooncol 2:289, 1984.
41. Lachance DH, Gockerman J, Halperin E: Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for primary central nervous system lymphoma (PCNSL): Short-duration response, multi-focal intracerebral recurrence preceding radiotherapy. Neurology 42:343, 1992.
42. Schultz C, Scott C, Wasserman T, et al: Pre-irradiation chemotherapy (CTX) with Cytoxan, Adriamycin, vincristine, and Decadron (CHOD) for primary central nervous system lymphomas (PCNSL): Initial report of Radiation Therapy Oncology Group (RTOG) protocol 88-06. Proc Am Soc Clin Oncol 13:174, 1994.
43. Liang BC, Grant R, Junck L, et al: Primary central nervous system lymphoma: Treatment with multiagent systemic and intrathecal chemotherapy with radiation therapy. Int J Oncol 3:1001-1004, 1993.
44. Brada M, Dearnaley D, Horwich A, et al: Management of primary cerebral lymphoma with initial chemotherapy. Int J Radiat Oncol Biol Phys 18:787-792, 1990.
45. Ott RJ, Brada M, Flower MA: Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer 27:1356-1361, 1991.
46. DeAngelis LM, Yahalom J, Rosenblum M, et al: Primary CNS lymphoma: Managing patients with spontaneous and AIDS-related disease. Oncology 1 :52-59, August 1987.
47. Nelson DF, Martz KL, Bonner H, et al: Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23:9-17, 1992.
48. Margolis L, Fraser R, Lichter A, et al: The role of radiation therapy in the management of ocular reticulum cell sarcoma. Cancer 45:688-692,1980.
49. Strauchen JA, Dalton J, Friedman AH: Chemotherapy in the management of intraocular lymphoma. Cancer 63:1918-1921, 1989.
50. Goldstein JD, Dickson DW, Moser FG, et al: Primary central nervous system lymphoma in acquired immune deficiency syndrome, a clinical and pathologic study with results of treatment with radiation. Cancer 67:2756-2765, 1991.
51. Gill PS, Levine AM, Meyer PR, et al: Primary central nervous system lymphoma in homosexual men: Clinical, immunologic, and pathologic features. Am J Med 78:742-748, 1985.
52. Formenti SC, Gill PS, Lean E, et al: Primary central nervous system lymphoma in AIDS: Results of radiation therapy. Cancer 63:1101-1107, 1989.
53. Chamberlain MC: Long survival in patients with acquired immune deficiency syndrome-related primary central nervous system lymphoma. Cancer 73:1728-1730, 1994.